COMPANY

Ting Therapeutics

HQ: San Diego, CA source · tingtherapeutics.com ↗ · West Coast

Also known as TING THERAPEUTICS LLC · 15 sources

Location: San Diego, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

13NIH grants

Funding and NIH signals

NIH award NIH awarded $524K (SBIR Phase II 5R44DC019065-05, continuation, notice Sep 17, 2026). NIH RePORTER 5R44DC019065-05 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 5R44DC019065-05
  Organization: TING THERAPEUTICS, INC.; City/State: San Diego, CA; Project number: 5R44DC019065-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 524299; Administering IC: National Institute on Deafness and Other Communication Disorders; Project title: Therapeutics to prevent aminoglycoside-induced hearing loss; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 17, 2026 Grant Government grant — SBIR: $524,299 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIDCD. Source: government award database. source ↗
Jul 24, 2025 Grant Government grant — SBIR: $524,300 (annual award, as published), announced Jul 24, 2025. Agency: NIH/NIDCD. Source: government award database. source ↗

Funding

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $524,299 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIDCD. Source: government award database. source ↗
Jul 24, 2025 Government grant — SBIR: $524,300 (annual award, as published), announced Jul 24, 2025. Agency: NIH/NIDCD. Source: government award database. source ↗

NIH awards 13

Annual award amounts. Total $4.2M.

Dec 5, 2024 NIH award 6R44DC018762-05 FY2024: $326,371 awarded for that fiscal year; activity R44 (SBIR); PI HUANG, YUNLONG; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. Preclinical evaluation of an otoprotectan source ↗
Dec 4, 2024 NIH award 6R44DC018463-05 FY2024: $174,684 awarded for that fiscal year; activity R44 (SBIR); PI HUANG, YUNLONG; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. CDK2 inhibitors for protecting hearing lo source ↗
Nov 19, 2024 NIH award 6R44DC019065-03 FY2024: $524,299 awarded for that fiscal year; activity R44 (SBIR); PI ZUO, JIAN; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. Therapeutics to prevent aminoglycoside-induced source ↗
Jul 17, 2024 NIH award 5R44DC018762-04 FY2024: supplement or administrative line (under $1,000); activity R44 (SBIR); PI HUANG, YUNLONG; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. Preclinical evaluation of an otoprotectant TT00 source ↗
Jul 17, 2024 NIH award 2R44DC019065-02A1 FY2024: supplement or administrative line (under $1,000); activity R44 (SBIR); PI ZUO, JIAN; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. Therapeutics to prevent aminoglycoside-induced hea source ↗
Dec 1, 2023 NIH award 5R44DC018463-04 FY2024: $176,763 awarded for that fiscal year; activity R44 (SBIR); PI HUANG, YUNLONG; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. CDK2 inhibitors for protecting hearing lo source ↗
Jul 20, 2023 NIH award 5R44DC018762-03 FY2023: $565,771 awarded for that fiscal year; activity R44 (SBIR); PI HUANG, YUNLONG; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. Preclinical evaluation of an otoprotectan source ↗
Dec 10, 2022 NIH award 5R44DC018463-03 FY2023: $541,332 awarded for that fiscal year; activity R44 (SBIR); PI HUANG, YUNLONG; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. CDK2 inhibitors for protecting hearing lo source ↗
Jul 26, 2022 NIH award 2R44DC018762-02A1 FY2022: $621,419 awarded for that fiscal year; activity R44 (SBIR); PI HUANG, YUNLONG; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. Preclinical evaluation of an otoprotect source ↗
Nov 4, 2021 NIH award 2R44DC018463-02A1 FY2022: $566,238 awarded for that fiscal year; activity R44 (SBIR); PI ZALLOCCHI, MARISA L.; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. CDK2 inhibitors for protecting he source ↗
Jul 17, 2020 NIH award 1R43DC019065-01 FY2020: $242,322 awarded for that fiscal year; activity R43 (SBIR); PI ZALLOCCHI, MARISA L.; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. Therapeutics to prevent aminoglycos source ↗
Mar 26, 2020 NIH award 1R43DC018762-01 FY2020: $205,736 awarded for that fiscal year; activity R43 (SBIR); PI SALEHI DERMANAKI, PEZHMAN; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. Therapeutics to prevent cispla source ↗
Dec 9, 2019 NIH award 1R43DC018463-01 FY2020: $220,653 awarded for that fiscal year; activity R43 (SBIR); PI ZALLOCCHI, MARISA L.; recipient as written: TING THERAPEUTICS, INC., San Diego, CA. CDK2 inhibitors for protecting hear source ↗